| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | 0.009 | 0.8 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.8 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.8 |
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | 0.0098 | 0.8 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.008 | 0.8 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.8 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.0077 | 0.8 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.8 |